Although mimics of human tumor antigens are effective immunogens to overcome host unresponsiveness to the nominal antigen, the structural basis of this mimicry remains poorly defined. Therefore, in this study we have characterized the structural basis of the human high molecular weight-melanoma-associated antigen (HMW-MAA) mimicry by the mouse anti-idiotypic (anti-id) monoclonal antibody (mAb) MK2-23. Using x-ray crystallography, we have characterized the three-dimensional structure of the anti-id mAb MK2-23 Fab and shown that its heavy chain complementarity-determining region (CDR3) (H3) and its light chain CDR1 (L1) are closely associated. These moieties are the source of HMW-MAA mimicry, since they display partial amino acid sequence homology along with a similar structural fold with the HMW-MAA core protein. Furthermore, a 15-residue peptide comprising the H3 loop of anti-id mAb MK2-23 demonstrates HMW-MAA-like in vitro and in vivo reactivity. This peptide in conjunction with the structural data will facilitate the characterization of the effect of the degree of antigen mimicry on the induction of a self-antigen-specific immune response by a mimic.Antigen mimicry has been implicated in the pathogenesis of several pathophysiological conditions such as viral immune evasion (1-3) and autoimmunity (4 -7). In these situations, the structurally similar foreign moieties either interfere with the normal biological functions mediated by their nominal counterparts or elicit unwanted immune responses against the host antigens. The consequences sometimes can be quite detrimental. Nevertheless, in the case of autoimmune responses mediated by molecular mimicry, an intriguing finding is the restriction of the damage to an organ or a tissue. This pattern is distinct from the general immune hyper-responsiveness caused by suppression of the regulatory arm of the immune system, such as cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade (8, 9).The potential ability of molecular mimicry to target a specific host antigen has provided the rationale for its use to elicit and/or enhance an immune response against human tumor antigens that are mostly non-mutated self-antigens and therefore poorly or non-immunogenic in patients (for review, see Refs. 10 and 11). Various types of tumor antigen mimics have been identified (for review, see Ref. 11). Among them the most extensively utilized is represented by antiidiotypic (anti-id) 4 monoclonal antibodies (mAb), which have been developed in several human tumor antigen systems (for review, see Refs. 10 and 11). Anti-id mAb markedly differ in their immunogenicity as measured by their ability to elicit a humoral immune response to the corresponding self-tumor antigen. The cause of this variability is not known. The lack of this information reflects, at least in part, the limited knowledge about the structural basis of antigen mimicry by anti-id antibodies and about the relationship between the extent of antigen mimicry and ability of a mimic to overcome unresponsiveness to a self-tumor antig...